Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

被引:0
|
作者
Yilmaz, Mukaddes [1 ]
Basak, Mustafa [2 ]
Ozyukseler, Deniz Tataroglu [3 ]
Yildirim, Mahmut Emre [4 ]
Arik, Zafer [5 ]
Salman, Mehmet Coskun [6 ]
Gultekin, Murat [6 ]
Akgor, Utku [7 ]
Inci, Bediz Kurt [8 ]
Gurler, Fatih [9 ]
Yucel, Kadriye Bir [10 ]
Savas, Gozde [10 ]
Onan, Mehmet Anil
Sunar, Veli [12 ]
Meydanli, Mehmet Mutlu [11 ,13 ]
Yazici, Ozan
Ozet, Ahmet [10 ]
机构
[1] Sivas Cumhuriyet Univ, Dept Med Oncol, Fac Med, Sivas, Turkiye
[2] Gazi Osman Pasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkiye
[3] Fethi Sekin State Hosp, Dept Med Oncol, Elazig, Turkiye
[4] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
[5] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkiye
[6] Hacettepe Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[7] Ankara Numune Training & Res Hosp, Dept Gynecol Oncol, Ankara, Turkiye
[8] Kirsehir Training & Res Hosp, Dept Med Oncol, Kirsehir, Turkiye
[9] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Med Oncol, Ankara, Turkiye
[10] Gazi Univ, Dept Med Oncol, Fac Med, Ankara, Turkiye
[11] Gazi Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[12] Aydin Ataturk State Hosp, Dept Med Oncol, Aydin, Turkiye
[13] Med Pk Hosp, Dept Gynecol Oncol, Gaziantep, Turkiye
来源
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY | 2023年
关键词
Interval debulking; neoadjuvant chemotherapy; ovarian carcinoma; primary debulking; CANCER; SURVIVAL; CYTOREDUCTION; OUTCOMES;
D O I
10.5505/tjo.2023.3883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE The aim of the study is to compare treatment outcomes of the patients with federation of gynecology and obstetrics stages III and IV ovarian carcinomas, who underwent interval debulking surgery after neoadjuvant chemotherapy (NACT), and patients who underwent adjuvant chemotherapy after primary debulking surgery (PDS). METHODS Patients from four centers (n=183) were retrospectively evaluated. Of the patients, 91 (50%) were in the PDS group and 92 (50%) in the NACT group. RESULTS In the NACT group patients have advanced age, poor performance status, high levels of CA125, and advanced disease stage compared with the PDS group (p<0.050). Of the patients receiving NACT, 14 (15%) had a complete response, and 68 (74%) had a partial response. The R0 rate was higher in the PDS group (p=0.018). In univariate analysis, poor prognostic factors affecting OS were NACT in the treatment protocol (p<0.001), poor performance status (p<0.001), advanced age (<70 vs. >= 70, p=0.002), advanced clinical stage (p=0.042), and localization of the tumor with the largest diameter outside the omentum and ovary at the time of diagnosis (p=0.029). In the multivariate analysis, the presence of NACT (HR: 2.30, 95% CI: 1.25-4.23, p=0.007) and poor performance (HR: 2.52, 95% CI: 1.18-5.10, p=0.017) were independent poor prognostic factors for OS. CONCLUSION In the study, OS was better in the PDS group than in the NACT group. This result was thought to be associated with the NACT group having more disadvantageous characteristics (advanced age, poor performance, high CA125 level, advanced stage, etc.).
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [31] Primary site disease and recurrence location in ovarian cancer patients undergoing primary debulking surgery vs. interval debulking surgery
    Andrea, Capozzi Vito
    Uccella, Stefano
    Sozzi, Giulio
    Ceccaroni, Marcello
    Mautone, Daniele
    Armano, Giulia
    Franchi, Massimo
    Chiantera, Vito
    Berretta, Roberto
    EJSO, 2021, 47 (05): : 1075 - 1082
  • [32] Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands
    Timmermans, M.
    Sonke, G. S.
    van Driel, W. J.
    Lalisang, R. I.
    Ottevanger, P. B.
    de Kroon, C. D.
    Van de Vijver, K. K.
    van der Aa, M. A.
    Kruitwagen, R. F.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 223 : 98 - 102
  • [33] Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review
    Ahmad, Zeeshanuddin
    Jain, Amar
    Mehta, Nikhil
    Saldanha, Elroy
    Patel, Dhruv
    Desai, Sanjay M.
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (01)
  • [34] Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection
    Gill, Sarah E.
    McGree, Michaela E.
    Weaver, Amy L.
    Cliby, William A.
    Langstraat, Carrie L.
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 266 - 273
  • [35] Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis
    Tzanis, Alexander A.
    Iavazzo, Christos
    Hadjivasilis, Alexandros
    Tsouvali, Hara
    Antoniou, George A.
    Antoniou, Stavros A.
    ONCOLOGY REVIEWS, 2022, 16
  • [36] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    da Costa, Alexandre A. B. A.
    Valadares, Camila V.
    Baiocchi, Glauco
    Mantoan, Henrique
    Saito, Augusto
    Sanches, Solange
    Guimaraes, Andreia P.
    Achatz, Maria Isabel W.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S971 - S978
  • [37] The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery
    Bizzarri, Nicolo
    Marchetti, Claudia
    Conte, Carmine
    Loverro, Matteo
    Giudice, Maria Teresa
    Quagliozzi, Lorena
    Distefano, Mariagrazia
    Chiantera, Vito
    Scambia, Giovanni
    Fagotti, Anna
    GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 453 - 458
  • [38] Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery
    Majd, Hooman Soleymani
    Ismail, Lamiese
    Hardern, Kieran
    Ferrari, Federico
    Kehoe, Sean
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 37 (01) : 89 - 92
  • [39] Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer
    Tsolakidis, D.
    Amant, F.
    Van Gorp, T.
    Leunen, K.
    Neven, P.
    Vergote, I.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 489 - 496
  • [40] Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer
    Khalil, Kheyal Azam
    Habib, Maria
    Usmani, Afshan Saeed
    Shah, Muhammad Ansab
    Anwer, Abdul Wahid
    Syed, Aamir Ali
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2025, 75 (04) : 583 - 586